rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    KAPA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
      Nov 5Yahoo FinanceKAPA
      Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
      Nov 3Yahoo FinanceKAPA
      Kairos Pharma at LD Micro Main Event: antibody bets on resistance
      Oct 21Investing.comKAPA
      Why Is Kairos Pharma Stock Falling Today? - Kairos Pharma (AMEX:KAPA)

      Kairos Pharma evaluates ENV-105 with apalutamide in a Phase 2 trial targeting drug-resistant metastatic prostate cancer patients.

      Oct 6BenzingaKAPA
      Kairos Pharma reports positive interim data for prostate cancer trial
      Oct 6Investing.comKAPA
      Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
      Oct 6Yahoo FinanceKAPA
      Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

      LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the 24th Annual Discovery on Target Drug Discovery Conference. The conference is being held on Sept. 28 to Oct. 1 at the Sheraton Boston Hotel with sessions available on demand on the conference’s website.

      Sep 23Yahoo FinanceKAPA
      Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus
      Sep 14Investing.comKAPA
      Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

      LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14 – 16, 2026 at the Lotte New York Palace Hotel.

      Sep 9Yahoo FinanceKAPA
      Kairos Pharma to conduct 1-for-7 reverse stock split
      Aug 21Investing.comKAPA
      Kairos Pharma Announces 1-for-7 Reverse Stock Split

      LOS ANGELES, August 21, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-7 (the "Reverse Stock Split"). The Reverse Stock Split is expected to become effective on September 1, 2026 at 12:01 a.m. ET (the "Effective Time"), with shares expected to begin trading on the NYSE American on a spli

      Aug 21Yahoo FinanceKAPA

      This is the newest page. Registered accounts read further back.